呼吸器内科学HP http://kokyu-kpum.com/
大学院科目名 | 呼吸器内科学 | ||
医学部教室名 | 内科学教室(呼吸器内科学部門) | ||
スタッフ |
准教授 山田 忠明
講師 金 永学
講師 金子 美子(教育センター)
助教 徳田 深作
助教 岩破 將博
助教 森本 吉恵(化学療法センター)
助教 大月 亮三(北部医療センター)
助教 吉村 彰紘(創薬センター)
|
||
研究内容 |
当科では、呼吸器疾患を研究対象に、その本態解明および新規診断・治療法開発を目指した基礎・橋渡し・臨床研究を精力的に進めています。また国内外の研究施設との共同研究を行っております。主な研究テーマは以下となります。
1)肺がん分子標的治療耐性に関する研究
2) がん悪液質に関する研究 3) 喫煙による薬剤感受性に関する研究 4) がん免疫治療に関する研究 5) がん微小環境に関する研究 6) 慢性呼吸不全に関する研究 |
||
研究業績 |
(2020年の主な業績)
1) Mouri T, et al. Education Program for Male Patients with Chronic Obstructive Pulmonary Disease to Change Dietary Behavior.
Kobe J Med Sci. 2020 Oct 12;66(3):E82-E89. 2) Nishioka N, et al. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.
Cancer Med. 2021 Jan;10(1):247-256. 3) Morimoto K, et al. Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Med Oncol. 2020 Nov 11;37(12):111. 4) Katayama Y, et al. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Sci Rep. 2020 Oct 15;10(1):17495. 5) Hamashima R, et al. Association of immune checkpoint inhibitors with respiratory infections: A review.
Cancer Treat Rev. 2020 Nov;90:102109. 6) Wang R, et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Nat Commun. 2020 Sep 14;11(1):4607. 7) Ikeda K, et al. Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients.
Nephron. 2020;144(10):525-536. 8) Sakakida T, et al. Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies.
Oncol Lett. 2020 Oct;20(4):14. 9) Matsui Y, et al. Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy.
Respirol Case Rep. 2020 Jul 16;8(7):e00625. 10) Kaneko Y, et al. The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status.
Intern Med. 2020;59(13):1605-1610. 11) Okura N, et al. Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
J Clin Med. 2020 Jun 29;9(7):2033. 12) Kobayashi K, et al. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Lung Cancer. 2020 Aug;146:236-243. 13) Igawa S, et al. Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
Lung Cancer. 2020 Aug;146:160-164. 14) Yamada T, et al. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
Ther Adv Med Oncol. 2020 May 28;12:1758835920927841. 15) Nakao A, et al. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.
J Clin Med. 2020 Jun 5;9(6):1762. 16) Takayama K, et al. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Oncologist. 2020 Aug;25(8):e1146-e1157.
17) Onoi K, et al. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
J Clin Med. 2020 May 6;9(5):1362. 18) Takayama K, et al. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist. 2020 Mar;25(3):208-e417. 19) Chihara Y, et al. Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis.
Int J Oncol. 2020 Mar;56(3):848-856. 20) Sekine I, et al. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
Cancer Sci. 2020 May;111(5):1685-1691. 21) Kaneko Y, et al. Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis.
Allergol Int. 2020 Jul;69(3):465-467. 22) Okura N, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Clin Cancer Res. 2020 May 1;26(9):2244-2256. |
||
問い合わせ先 | TEL:075-251-5513 FAX:075-251-5376 e-mail:takayama@koto.kpu-m.ac.jp |
||
教室独自のHP | http://kokyu-kpum.com/ |